VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

L. Morasca, S. Marsoni, M. Brambilla Pisoni, E. Piazza, G. Vago, W. Casali, R. Cogo, C. Bainchi, R. Scapaticci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.

Original languageEnglish
Pages (from-to)209-210
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume7
Issue number2-3
DOIs
Publication statusPublished - 1982

Fingerprint

Small Cell Carcinoma
Bronchogenic Carcinoma
Cyclophosphamide
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Morasca, L., Marsoni, S., Pisoni, M. B., Piazza, E., Vago, G., Casali, W., ... Scapaticci, R. (1982). VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. Cancer Chemotherapy and Pharmacology, 7(2-3), 209-210. https://doi.org/10.1007/BF00254551

VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. / Morasca, L.; Marsoni, S.; Pisoni, M. Brambilla; Piazza, E.; Vago, G.; Casali, W.; Cogo, R.; Bainchi, C.; Scapaticci, R.

In: Cancer Chemotherapy and Pharmacology, Vol. 7, No. 2-3, 1982, p. 209-210.

Research output: Contribution to journalArticle

Morasca, L, Marsoni, S, Pisoni, MB, Piazza, E, Vago, G, Casali, W, Cogo, R, Bainchi, C & Scapaticci, R 1982, 'VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma', Cancer Chemotherapy and Pharmacology, vol. 7, no. 2-3, pp. 209-210. https://doi.org/10.1007/BF00254551
Morasca L, Marsoni S, Pisoni MB, Piazza E, Vago G, Casali W et al. VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. Cancer Chemotherapy and Pharmacology. 1982;7(2-3):209-210. https://doi.org/10.1007/BF00254551
Morasca, L. ; Marsoni, S. ; Pisoni, M. Brambilla ; Piazza, E. ; Vago, G. ; Casali, W. ; Cogo, R. ; Bainchi, C. ; Scapaticci, R. / VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma. In: Cancer Chemotherapy and Pharmacology. 1982 ; Vol. 7, No. 2-3. pp. 209-210.
@article{da0b6509b0334b8aa124e1fd7c10fd3a,
title = "VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma",
abstract = "Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.",
author = "L. Morasca and S. Marsoni and Pisoni, {M. Brambilla} and E. Piazza and G. Vago and W. Casali and R. Cogo and C. Bainchi and R. Scapaticci",
year = "1982",
doi = "10.1007/BF00254551",
language = "English",
volume = "7",
pages = "209--210",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2-3",

}

TY - JOUR

T1 - VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

AU - Morasca, L.

AU - Marsoni, S.

AU - Pisoni, M. Brambilla

AU - Piazza, E.

AU - Vago, G.

AU - Casali, W.

AU - Cogo, R.

AU - Bainchi, C.

AU - Scapaticci, R.

PY - 1982

Y1 - 1982

N2 - Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.

AB - Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1-3, every 3 weeks. Partial remissions were seen in 2 of 27 evaluable patients; 16 of 27 showed no change. Mean survival was 36.4 weeks, median survival was 38 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0020045458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020045458&partnerID=8YFLogxK

U2 - 10.1007/BF00254551

DO - 10.1007/BF00254551

M3 - Article

C2 - 7083461

AN - SCOPUS:0020045458

VL - 7

SP - 209

EP - 210

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2-3

ER -